ChromaDex and American Laboratories Collaborate to Provide Identity Test for Glandular Related Ingredients

ChromaDex’s ComplyID™ Identity Testing Program to Help Dietary Supplement Companies Meet FDA Requirements

Dec. 17, 2015 6:30 am

IRVINE, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC) and American Laboratories, Inc. (ALI) announced today the release of a Fourier Transform Near Infrared (FT-NIR) based identification method for the positive identification of desiccated bovine and porcine glandular tissues used in nutritional product formulations.

ChromaDex has developed a FT-NIR algorithm and cluster based analysis model under its ComplyID™ program to individually identify eighteen bovine and porcine glands provided by ALI. The ComplyID™ model has the ability to find unique spectral differences with each of the 18 glandular materials for proper identification and verification of glandular material.

ChromaDex’s ComplyID™ program is designed to help dietary supplement companies meet the minimum identity testing requirements under the FDA’s Dietary Supplement Current Good Manufacturing Practice (cGMP) Rule FDA 21 CFR Part 111.

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, “Compliance with the FDA 21 CFR part 111, the Dietary Supplement cGMPs, continues to be a critical issue for the industry. Staying in compliance is an ongoing effort for all companies because interpretation and enforcement continues to evolve. Many companies have been surprised to find that their initial quality systems are no longer adequate in today’s regulatory climate. We are pleased to collaborate with ALI to provide the industry with an identity test for glandular related ingredients.”

About American Laboratories, Inc.:

American Laboratories, Inc. (ALI) was started in 1967 in Omaha, NE. ALI is a specialty processor of Enzymes (Pancreatin, Pepsin, Bromelain, Papain, Fungal and Custom Fungal Enzyme Blends); Proteins (Beef, Pork and Chicken Liver Powders. Desiccated glandular tissues); and Peptones (Casein Hydrolysate, Microbiotone, and Proteose Micro) and sells to the food processing, pharmaceutical, veterinary health, human nutritional, and companion animal industries in 45 countries around the world. For more information, visit 
About ChromaDex:

ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; ProC3G®, a natural black rice containing cyanidin-3-glucoside; IMMULINA, a spirulina extract; and Suntava® Purple Corn derived from a proprietary non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please visit

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2015, the Company’s Quarterly Reports on Form 10-Q, the Company’s Current Reports on Form 8-K and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.


American Laboratories, Inc. Company Contact:

Bret Wyant
Vice President of Sales

ChromaDex Company Contact:

Andrew Johnson
Director of Investor Relations

ChromaDex Investor Contacts:                                            

The Del Mar Consulting Group, Inc.
Robert B. Prag, President

Primary Logo

December 17, 2015 - 6:30 AM EST

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market